| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 10/23/2023 | 43.36% | Raymond James | $138 → $160 | Maintains | Strong Buy |
| 10/06/2023 | 18.27% | JP Morgan | $131 → $132 | Maintains | Overweight |
| 09/14/2023 | 5.73% | Jefferies | $115 → $118 | Maintains | Hold |
| 08/18/2023 | 17.37% | Morgan Stanley | → $131 | Upgrades | Underweight → Equal-Weight |
| 08/02/2023 | 17.37% | Morgan Stanley | $131 → $131 | Reiterates | Underweight → Underweight |
| 07/27/2023 | 17.37% | Morgan Stanley | $130 → $131 | Maintains | Underweight |
| 07/17/2023 | 9.31% | Wells Fargo | $121 → $122 | Maintains | Equal-Weight |
| 06/09/2023 | 13.79% | Keefe, Bruyette & Woods | → $127 | Reiterates | → Market Perform |
| 05/15/2023 | 8.41% | Wells Fargo | $120 → $121 | Maintains | Equal-Weight |
| 05/05/2023 | 3.04% | Truist Securities | $125 → $115 | Maintains | Hold |
| 05/05/2023 | 16.48% | Piper Sandler | $135 → $130 | Maintains | Overweight |
| 05/04/2023 | 16.48% | Morgan Stanley | $129 → $130 | Maintains | Underweight |
| 04/25/2023 | 7.52% | Wells Fargo | → $120 | Initiates Coverage On | → Equal-Weight |
| 04/12/2023 | 15.58% | Morgan Stanley | $133 → $129 | Maintains | Underweight |
| 03/14/2023 | 23.64% | Raymond James | $141 → $138 | Maintains | Strong Buy |
| 02/24/2023 | 19.16% | Morgan Stanley | $132 → $133 | Maintains | Underweight |
| 02/15/2023 | 26.33% | Raymond James | $138 → $141 | Maintains | Strong Buy |
| 02/03/2023 | 12% | Truist Securities | $112 → $125 | Maintains | Hold |
| 01/10/2023 | 18.27% | Morgan Stanley | $115 → $132 | Maintains | Underweight |
| 01/06/2023 | 12.89% | JP Morgan | $112 → $126 | Maintains | Overweight |
| 12/20/2022 | 16.48% | Piper Sandler | $127 → $130 | Maintains | Overweight |
| 12/19/2022 | 25.44% | Credit Suisse | $130 → $140 | Maintains | Outperform |
| 11/17/2022 | 3.04% | Morgan Stanley | $112 → $115 | Maintains | Underweight |
| 10/28/2022 | 0.35% | Truist Securities | $100 → $112 | Maintains | Hold |
| 10/28/2022 | 2.14% | Evercore ISI Group | $115 → $114 | Downgrades | Outperform → In-Line |
| 10/27/2022 | 0.35% | Morgan Stanley | $110 → $112 | Maintains | Underweight |
| 09/22/2022 | 23.64% | Raymond James | → $138 | Initiates Coverage On | → Strong Buy |
| 08/17/2022 | -1.44% | Morgan Stanley | $109 → $110 | Maintains | Underweight |
| 07/28/2022 | -2.34% | Morgan Stanley | $107 → $109 | Maintains | Underweight |
| 07/11/2022 | 0.35% | JP Morgan | $108 → $112 | Maintains | Overweight |
| 07/08/2022 | 8.41% | Piper Sandler | $119 → $121 | Maintains | Overweight |
| 06/15/2022 | 0.35% | Evercore ISI Group | $105 → $112 | Upgrades | In-Line → Outperform |
| 02/22/2022 | -4.13% | Morgan Stanley | $105 → $107 | Maintains | Underweight |
| 01/26/2022 | -5.03% | Jefferies | → $106 | Initiates Coverage On | → Hold |
| 01/21/2022 | -23.84% | Wolfe Research | → $85 | Initiates Coverage On | → Underperform |
| 01/12/2022 | 4.83% | Piper Sandler | $105 → $117 | Upgrades | Neutral → Overweight |
| 01/07/2022 | -5.92% | Morgan Stanley | $103 → $105 | Maintains | Underweight |
| 11/18/2021 | -7.71% | Morgan Stanley | $105 → $103 | Maintains | Underweight |
| 10/19/2021 | 16.48% | Credit Suisse | $135 → $130 | Maintains | Outperform |
| 07/22/2021 | -0.55% | JP Morgan | $110 → $111 | Maintains | Overweight |
| 07/12/2021 | -1.44% | JP Morgan | $109 → $110 | Maintains | Overweight |
| 07/08/2021 | -10.4% | Piper Sandler | $105 → $100 | Maintains | Neutral |
| 06/07/2021 | 20.96% | Credit Suisse | $122 → $135 | Maintains | Outperform |
| 05/19/2021 | -5.92% | Morgan Stanley | $100 → $105 | Maintains | Underweight |
| 04/05/2021 | -7.71% | JP Morgan | $99 → $103 | Maintains | Overweight |
| 04/01/2021 | -10.4% | Morgan Stanley | $95 → $100 | Maintains | Underweight |
| 02/25/2021 | -14.88% | Morgan Stanley | $93 → $95 | Maintains | Underweight |
| 01/15/2021 | -16.67% | Morgan Stanley | $92 → $93 | Maintains | Underweight |
| 12/04/2020 | 9.31% | Credit Suisse | $109 → $122 | Maintains | Outperform |
| 11/18/2020 | -17.57% | Morgan Stanley | $86 → $92 | Maintains | Underweight |
| 10/23/2020 | -22.95% | Truist Securities | $81 → $86 | Maintains | Hold |
| 10/22/2020 | -11.3% | JP Morgan | $97 → $99 | Maintains | Overweight |
| 10/22/2020 | -22.95% | Morgan Stanley | $84 → $86 | Maintains | Underweight |
| 10/06/2020 | -24.74% | Morgan Stanley | $82 → $84 | Maintains | Underweight |
| 08/20/2020 | -26.53% | Morgan Stanley | $80 → $82 | Maintains | Underweight |
| 07/23/2020 | -28.32% | Morgan Stanley | $78 → $80 | Maintains | Underweight |
| 07/06/2020 | -30.11% | Morgan Stanley | $72 → $78 | Maintains | Underweight |
| 07/02/2020 | -31.01% | Piper Sandler | $87 → $77 | Maintains | Neutral |
| 06/05/2020 | -22.05% | Piper Sandler | → $87 | Initiates Coverage On | → Neutral |
| 04/24/2020 | -29.22% | SunTrust Robinson Humphrey | $108 → $79 | Maintains | Hold |
| 04/23/2020 | -35.49% | Morgan Stanley | $73 → $72 | Maintains | Underweight |
| 04/07/2020 | -10.4% | JP Morgan | $106 → $100 | Maintains | Overweight |
| 03/17/2020 | -34.59% | Morgan Stanley | $91 → $73 | Maintains | Underweight |
| 01/23/2020 | 4.83% | B of A Securities | $110 → $117 | Maintains | Buy |
| 01/02/2020 | -5.03% | JP Morgan | $100 → $106 | Maintains | Overweight |
| 11/15/2019 | -21.15% | Morgan Stanley | $87 → $88 | Maintains | Underweight |
| 10/10/2019 | -24.74% | UBS | $85 → $84 | Maintains | Sell |
| 09/20/2019 | 2.14% | Credit Suisse | → $114 | Initiates Coverage On | → Outperform |
What is the target price for Globe Life (GL)?
The latest price target for Globe Life (NYSE: GL) was reported by Raymond James on October 23, 2023. The analyst firm set a price target for $160.00 expecting GL to rise to within 12 months (a possible 43.36% upside). 26 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Globe Life (GL)?
The latest analyst rating for Globe Life (NYSE: GL) was provided by Raymond James, and Globe Life maintained their strong buy rating.
When is the next analyst rating going to be posted or updated for Globe Life (GL)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Globe Life, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Globe Life was filed on October 23, 2023 so you should expect the next rating to be made available sometime around October 23, 2024.
Is the Analyst Rating Globe Life (GL) correct?
While ratings are subjective and will change, the latest Globe Life (GL) rating was a maintained with a price target of $138.00 to $160.00. The current price Globe Life (GL) is trading at is $111.61, which is out of the analyst's predicted range.